Patents Examined by Sergio Coffa
  • Patent number: 11325949
    Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest including plants, as probes for the isolation of other homologous (or partially homologous) genes. The pesticidal proteins find use in controlling, inhibiting growth or killing Lepidopteran, Coleopteran, Dipteran, fungal, Hemipteran and nematode pest populations and for producing compositions with insecticidal activity.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: May 10, 2022
    Inventors: Scott Diehn, James J English, Lu Liu, Azalea S Ong, Jarred Kenneth Oral, Barbara Rosen, Ute Schellenberger, Ingrid Udranszky, Jun-Zhi Wei, Weiping Xie, Genhai Zhu
  • Patent number: 11311633
    Abstract: The present application provides methods and compositions for AAV-mediated delivery of PYY and Glucagon-like Peptide 1 or an analog thereof (e.g., Exendin-4) to a subject (e.g., the saliva of a subject). In some embodiments, compositions and methods for topical delivery of Ex-4 and PYY peptides also are provided. Methods and compositions are useful to promote weight loss and/or altered lipid taste sensitivity, as well as for the treatment of diabetes.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: April 26, 2022
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Sergei Zolotukhin, Sean M. Crosson, Cedrick Shawn Dotson, Seth Currlin, Andres Acosta
  • Patent number: 11304989
    Abstract: Disclosed are peptides, compositions, combinations, kits and methods for the treatment of viral pathogen infection. Combinations and kits comprise the disclosed peptides together with an additional antiviral therapeutic agent.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: April 19, 2022
    Inventors: Raymond Kaempfer, Gila Arad
  • Patent number: 11286287
    Abstract: This disclosure is directed to compositions comprised of antimicrobial peptides (AMPs) having an alpha helical structure wherein one side is highly hydrophobic. Representative sequences of the antimicrobial peptides include ILKKWW????GLLG?LLG?V??VIK?L??I (SEQ ID No. 2), LKKWWK??KGLLGGLLGKV??VIK (SEQ ID No. 12), and ?KK??KK?KG?LGGL?GK (SEQ ID No. 18). Additional embodiments disclose methods for treating a microbial infection; reducing biofilm; decreasing inflammation; and treating infectious diseases, COPD, asthma, pulmonary fibrosis, cystic fibrosis, rhinosinusitis, septicemia, RSV, TB or cancer; in a subject in need thereof comprising administering to the subject a therapeutic amount of an antimicrobial peptide.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: March 29, 2022
    Inventors: Berthony Deslouches, Yuanpu Di
  • Patent number: 11273118
    Abstract: Provided herein are methods for improving skin quality in a subject comprising administering to the skin a pharmaceutical composition comprising a polypeptide covalently bound to a hydrophilic polymer and/or a polysaccharide covalently bound to a hydrophilic polymer.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: March 15, 2022
    Assignee: Zim Biosciences, Inc.
    Inventors: Jane M. Meyer, Nikita Malavia, Stephen Alexander Charles
  • Patent number: 11266718
    Abstract: A method for treating, remedying, or preventing inflammatory skin disorders by administering a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing an inflammatory skin disorder by administering topically and to the pre-psoriatic rim a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation.
    Type: Grant
    Filed: May 30, 2020
    Date of Patent: March 8, 2022
    Assignee: NEPSONE EHF
    Inventor: Birkir Sveinsson
  • Patent number: 11267863
    Abstract: Disclosed are a novel N-terminal fusion partner, a fusion polypeptide including the fusion partner and a target polypeptide, and a method for producing a target polypeptide using the same. The novel fusion partner can enhance the yield of a target polypeptide (recombinant polypeptide) compared to the conventional fusion partners. Using the novel fusion partner is particularly beneficial in producing a target polypeptide having a relatively low molecular weight and an easily degradable amino terminus based on genetic recombination technologies. Further, the novel fusion polypeptide including the fusion partner can be expressed as inclusion bodies in a host cell and protected against proteases or the like in a host cell, which makes the target polypeptide produced stably. Therefore, in comparison to the conventional fusion partners, the novel fusion partner can be used to provide a method for producing a recombinant peptide with improved stability and yield.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: March 8, 2022
    Assignee: PEPGENE INC.
    Inventor: Sung Gun Kim
  • Patent number: 11254707
    Abstract: Providing a method for selecting minerals containing arsenic. A peptide comprising an amino acids sequence according to the following formula: (T, S, N, or Q)-(H, P, or W)-(E, or D)-(H, P, W, R, or K)-(L, I, V, F, or A)-(L, I, V, F, or A)-(L, I, V, F, or A)-(T, S, N, or Q)-(H, P, or W)-(L, I, V, F, or A)-(T, S, N, or Q)-(L, I, V, F, or A) wherein one amino acid is respectively selected from each group defined by paired parentheses.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: February 22, 2022
    Inventors: Mitsuo Yamashita, Akira Miura
  • Patent number: 11254706
    Abstract: Hepatitis C virus (HCV) infection is a leading cause for liver cirrhosis and hepatocellular carcinoma worldwide2. Current therapeutic regimens are usually poorly tolerated and only effective in a proportion of infected individuals. We discovered a peptide with sequence of DEAQETAVSSHEQD (SEQ ID NO: 1), a fragment of rabbit ?1-antiproteinase F, and its derivatives DEAQETAVSSHEQ (SEQ ID NO: 2) and QETAVSSHEQD (SEQ ID NO: 3), significantly inhibit serum-borne HCV replication in hADSC and human hepatocytes.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: February 22, 2022
    Assignee: Inno Bio-Drug Development Limited
    Inventor: Chen-Lung Lin
  • Patent number: 11248030
    Abstract: Dual receptor binding compounds comprising IL-2R?, IL-7R?, and R?c ligands, and pharmaceutical compositions comprising the dual receptor binding compounds are disclosed. The dual receptor binding compounds can act as IL-2R and IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: February 15, 2022
    Assignee: MEDIKINE, INC.
    Inventors: William J. Dower, Michael C. Needels, Ronald W. Barrett, Alice V. Bakker, Steven E. Cwirla
  • Patent number: 11236142
    Abstract: The present invention relates to a novel peptide analog of acylated oxyntomodulin and a pharmaceutical composition comprising the same for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptides are superior to those of natural oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition comprising said peptides is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: February 1, 2022
    Assignee: DONG-A ST CO., LTD.
    Inventors: Jae-Sung Yang, Kyung-Seok Lee, Yu-Na Chae, Gye-Rim Baek, Tae-Hyoung Kim, Ill-Hun Jung, Chae-Lim Ryu, Weon-Bin Im
  • Patent number: 11220669
    Abstract: Described is a three-dimensional (3D) microenvironment presenting defined biochemical and physical cues that regulate cellular behavior and use of the microenvironment. A composition to form the 3D microenvironment is provided by combining one or more natural or synthetic polymeric materials and substrate proteins recombinantly or chemically functionalized with a variety of bioactive peptides such as extracellular matrix-derived or growth factor-derived peptides. Also described are devices and methods for screening for optimal combinations of the bioactive motifs in order to create an extracellular microenvironment that can regulate specific cellular behavior such as cell growth, proliferation, migration or differentiation.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: January 11, 2022
    Assignees: Amolifescience Co., Ltd., Kollodis BioSciences, Inc.
    Inventors: Chan Kim, Kyuwon Baek, Hui-Gwan Goo, Sangjae Lee, Bongjin Hong, Song Hee Koo, In Yong Seo, Seung Hoon Lee, Ji Hyun Lee, Seonho Jang, Dong-Sik Seo
  • Patent number: 11219690
    Abstract: The invention relates to methods for obtaining a protein conjugate wherein a cysteine residue of the protein serves as attachment point for the chemical moiety conjugated to the protein.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: January 11, 2022
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Charlotte Schou Hunneche, Thomas Budde Hansen, Ernst Broberg Hansen
  • Patent number: 11208456
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: December 28, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
  • Patent number: 11179471
    Abstract: Provided is a peptide represented by the following formula (I): R1-IWLTALX5FLGX6X1AAX7X2X3AX8QX4LSX9L-R2?(I) wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, R1, and R2 are as defined in the specification.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: November 23, 2021
    Inventors: Shiroh Futaki, Kentarou Sakamoto, Misao Akishiba
  • Patent number: 11174299
    Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence consisting of SVHSFDYDWYNV, or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: November 16, 2021
    Assignee: DISPERSEBIO LTD.
    Inventor: Amir Zlotkin
  • Patent number: 11168113
    Abstract: (Technical problems to be solved) Providing a method for selecting an mineral of molybdenum. (Means for solving the problems) A peptide comprising an amino acids sequence according the following formula (1) and/or (2): (1) (ALRKNMD-FCPQSETGWHYIV)-(LIVFA)-(HPWRK)-(TSNQ)-(TSNQ)-(LIVFA)-(TSNQ)-(TSNQ)-(LIVFA)-(FYW)-(LIVFA)-(HPWRK) (2) (LIVFA)-(RHK)-(TSNQ)-(LIVFA)-(LIVFA)-(TSNQ)-(LIVFA)-(LIVFA)-(LIVFA)-(RHK)-(RHK)-(HPW) wherein one amino acid is respectively selected from each group defined by paired parentheses.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: November 9, 2021
    Inventors: Mitsuo Yamashita, Akira Miura
  • Patent number: 11155582
    Abstract: An antiviral peptide provided according to the present invention includes (1) an amino acid sequence (TM sequence) constituting a transmembrane region of G protein of vesicular stomatitis virus (VSV) or a modified amino acid sequence formed by conservative substitutions of 1, 2, or 3 amino acid residues in the TM sequence; and (2) an amino acid sequence (CPP sequence) functioning as a cell penetrating peptide (CPP), wherein a total number of amino acid residues is 100 or less.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: October 26, 2021
    Assignees: TOAGOSEI CO., LTD, National University Corporation Hokkaido University
    Inventors: Tetsuhiko Yoshida, Ayato Takada, Nahoko Baileykobayashi
  • Patent number: 11147856
    Abstract: The present invention relates to hot flash-suppressing agents and menopausal disorder-improving agents and a food and drink and a pharmaceutical preparation for suppressing hot flash, containing ?-lactalbumin as an active ingredient.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: October 19, 2021
    Assignee: MEIJI CO., LTD.
    Inventors: Masayuki Uchida, Orie Kobayashi
  • Patent number: 11142562
    Abstract: The present invention relates to a novel peptide that exhibits effective antimicrobial activity against various gram-positive and gram-negative bacteria that are involved in food-borne pathogenesis, food spoilage and other pathogenic conditions. Therefore, this peptide can be a good candidate as antibacterial in agricultural, food and beverage industry, as well as for other medical applications and societal use.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: October 12, 2021
    Assignee: Council of Scientific & Industrial Research
    Inventors: Balaji Prakash, Yashavanth Linganamane, Abhishek Acharya